Results from a recently published phase 1/2 multicenter clinical trial showed that the combination therapy of Dabrafenib, trametinib, and the autophagy inhibitor hydroxychloroquine was safe and effective in patients with BRAF-mutated melanoma [24,25]. The gene discussed is BRAF; the disease is melanoma.